Birth of the
Contribute to the initiative as we roll out the world's first gene-based targeted antiviral against the novel coronavirus SARS-CoV-2.
The Fight Against the COVID-19 Pandemic:
Hope for a Novel Drug
NuCISION was formed in March 2020 in response to the global pandemic caused by the COVID-19 virus, SARS-CoV-2.
The company was set up quickly as the founders were already involved in the decades-long development of an antisense complex drug that could address viral infections in a new, targeted way. Moreover, this solution improves on previous knowledge and provides a new way for nanopharmaceuticals to address viral invaders through new means of cell entry and complexing methods.
This solution will be brought to the market as RELIVIR®.
NuCISION has taken a different path and is not pursuing a vaccine or antibody approaches.
We recognize the market need for a novel therapeutic that does not only prevent viral replication as that of conventional antivirals, but also destroy viral RNA through novel methods like what RELIVIR does.
SARS-CoV-2 RNA is degraded through a novel drug complex that features improved cell entry, nucleotide-based inhibition and targeting, and enzymatic degradation.
RELIVIR® is expected to be effective in directly destroying the virus and disrupting viral replication with applications in multiple stages of the infection.
COVID-19 BY NUMBERS
*Updated as of February 12
Why a Novel Antiviral?
The overwhelming majority of drugs being used or explored in COVID-19 treatment today are repurposed. These are repurposed antivirals, anti-inflammatories or drugs with poorly understood mechanisms of action but with promising empirical evidence to support their use.
This means that no specific treatment for SARS-CoV-2 has yet been developed. Repurposed drugs, being non-specific to the disease agent, or directed at the complications of the disease, usually offer a less-than-ideal result and are often regarded as stop-gap measures until a specific or targeted drug has been developed.
Vaccine timelines are notoriously long, and the typical timeline is about a decade or longer. The options to shorten the development timeline may involve compromises in critical safety and efficacy. Should a vaccine prove to be effective, manufacturing a minimum of 14 billion doses (for a multi-dose approach) would be an unprecedented challenge.
Antibody-based treatments, though valuable in the approach to the disease, ranging from monoclonals to novel or synthetic antibodies. Monoclonal antibody therapies are difficult to scale. Discoveries in the antibody response to SARS-CoV-2 point to multiple antibodies formed by recovered patients but lead to more questions as to the length of immunity and the protective value of such antibodies.
There is a relative paucity in the development of tailored treatments that address the virus directly and have ideal features like scalability and adaptability to mutations.
The world's population of over 7 billion needs multiple types of drugs and platforms to control the pandemic.
Offers a groundbreaking novel solution to pandemic-causing viruses. Our technology offers a new approach using a combination of nanotech innovations to target the virus and degrade its RNA within the cell.
The World’s First Nano-guided Antiviral
Designed to Degrade SARS-CoV-2 within the Cell.
New Platform: A groundbreaking and completely novel therapeutic approach towards viral infections.
Effective method of drug delivery that successfully combines novel methods of nanoparticulate drug delivery and antisense targeting complexed with a simple viral degradation strategy.
High Level of biocompatibility, with Low Toxicity potential.
First TARGETED and SPECIFIC therapeutic for SARS-CoV-2.